Literature DB >> 8631535

Endometrial carcinoma--relative effectiveness of adjuvant irradiation vs therapy reserved for relapse.

I Ackerman1, S Malone, G Thomas, E Franssen, J Balogh, A Dembo.   

Abstract

Fifty-four patients with recurrent endometrial carcinoma were identified from a retrospective review of charts of 304 endometrial cancer patients seen between 1983 and 1989 at our center. A review was undertaken to identify the patterns of relapse, to determine the outcome of salvage treatment, to examine the factors predictive of effective salvage, and, if salvage is effective, to assess an alternative strategy to routine adjuvant postoperative pelvic radiotherapy. Forty percent of the entire recurrent population are long-term survivors. Of the 54 relapsing patients, primary therapy had been surgery alone in 32 and surgery and adjuvant radiotherapy (rt) in 22. Isolated pelvic recurrence was the predominate relapse site in those who had not received adjuvant pelvic RT as primary therapy (23 of 32 or 72%). Distant relapse predominated in those who received adjuvant RT (17 or 22 or 77%). Twenty-eight (54%) failed in the pelvis alone, and 26 (46%) had a component of distant failure. Of the 28 with isolated pelvic relapse, 16 had vaginal mucosal disease involvement only and 12 had disease in the parametrium and/or the pelvic sidewall. With a minimum follow-up for the survivors of 5 years, 21 of the 28 with isolated pelvic relapse received radical radiotherapy and 14 or 67% had maintained pelvic control until death or last follow-up. Eleven of 14 (79%) with disease confined to the mucosa had pelvic control, whereas only 3 of 7 (43%) with extramucosal disease were controlled. No patient experienced major treatment-related toxicity. Tumor size, anatomic extent of pelvic recurrence, RT dose, and disease-free interval were examined for prognostic significance for pelvic control and survival by univariate analysis. Only anatomic extent of pelvic recurrence showed a nonstatistically significant trend as a predictor for control with P = 0.08. In conclusion, a significant proportion of patients with disease recurrence confined to the pelvis can be rendered disease-free long-term with maintained pelvic control. A reexamination of the role of routine adjuvant pelvic RT is therefore undertaken in light of these data.

Entities:  

Mesh:

Year:  1996        PMID: 8631535     DOI: 10.1006/gyno.1996.0022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Management of stage 1 endometrial carcinoma. Postoperative radiotherapy is not justified in women with medium risk disease.

Authors:  M P Burger
Journal:  BMJ       Date:  2001-03-10

2.  Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006.

Authors:  Marco Johannes Battista; Marcus Schmidt; Nicole Rieks; Isabel Sicking; Stefan Albrich; Michael Eichbaum; Heinz Koelbl; Peter Mallmann; Gerald Hoffmann; Eric Steiner
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-26       Impact factor: 4.553

Review 3.  Hormonal therapy in advanced or recurrent endometrial cancer.

Authors:  Fani Kokka; Elly Brockbank; David Oram; Chris Gallagher; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

4.  What sampling device is the most appropriate for vaginal vault cytology in gynaecological cancer follow up?

Authors:  Lino Del Pup; Del Pup Lino; Vincenzo Canzonieri; Canzonieri Vincenzo; Diego Serraino; Serraino Diego; Elio Campagnutta; Campagnutta Elio
Journal:  Radiol Oncol       Date:  2012-04-11       Impact factor: 2.991

5.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

6.  Vaginal vault recurrences of endometrial cancer in non-irradiated patients - Radiotherapy or surgery.

Authors:  Hordur Alexander Hardarson; Lene Nyhøj Heidemann; René dePont Christensen; Ole Mogensen; Kirsten M Jochumsen
Journal:  Gynecol Oncol Rep       Date:  2015-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.